Drug-Induced Arrhythmia: Bridging the Gap Between Pathophysiological Knowledge and Clinical Practice Elisabetta PoluzziEmanuel RaschiFabrizio De Ponti Commentary 08 April 2017 Pages: 461 - 464
Adverse Drug Event Causality Analysis (ADECA): A Process for Evaluating Evidence and Assigning Drugs to Risk Categories for Sudden Death Raymond L. WoosleyKlaus RomeroSophie Ward Leading Article 08 March 2017 Pages: 465 - 474
Pharmacovigilance of Regenerative Medicine Under the Amended Pharmaceutical Affairs Act in Japan Yasuko Inokuma Leading Article 15 March 2017 Pages: 475 - 482
Evaluation of ‘SAEFVIC’, A Pharmacovigilance Surveillance Scheme for the Spontaneous Reporting of Adverse Events Following Immunisation in Victoria, Australia Hazel J. ClothierNigel W. CrawfordJim P. Buttery Original Research Article 24 March 2017 Pages: 483 - 495
Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals Andreas SchickKathleen L. MillerClark Nardinelli Original Research Article 24 March 2017 Pages: 497 - 503
The Risk of Ischemic Cardio- and Cerebrovascular Events Associated with Oxycodone–Naloxone and Other Extended-Release High-Potency Opioids: A Nested Case–Control Study Kathrin JobskiBianca KollhorstTania Schink Original Research Article 13 February 2017 Pages: 505 - 515
A Survey on Pharmacovigilance Activities in ASEAN and Selected Non-ASEAN Countries, and the Use of Quantitative Signal Detection Algorithms Cheng Leng ChanPei San AngShu Chuen Li Original Research Article 28 February 2017 Pages: 517 - 530
Patient and Physician Perceptions of Drug Safety Information for Sleep Aids: A Qualitative Study Aaron S. KesselheimSarah A. McGrawEric G. Campbell Original Research Article 28 February 2017 Pages: 531 - 542